RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 11:30:30时区推断·⟳ 抓取 11:45:32·⚡ 决策 07-23 11:51:10 +5m38s·96.3 天前
Revolution Medicines达拉昔拉西布NDA获FDA受理审评
FDA受理daraxonrasib用于既往治疗转移性胰腺导管腺癌的NDA，属于监管路径推进而非最终获批。
📄 原文RTTNews Biotech↗ 原文
Revolution Medicines' NDA For Daraxonrasib Accepted By FDA For Metastatic Pancreatic Cancer
Revolution Medicines, Inc. (RVMD) announced that the U.S. FDA has accepted for review its New Drug Application (NDA) fo…
不做 Revolution Medicines（RVMD.US）
不做：FDA受理NDA是正面但非最终批准，且关键疗效、扩展用药、EMA加速审评和NDA接近完成已提前传播；原文盘后仅小涨1.87%，当前追多edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- FDA此前已允许daraxonrasib扩大用药方案推进，说明监管支持信号并非首次出现。
- 公司披露EMA启动分阶段审评，并称美国NDA滚动提交接近完成，提前铺垫了本次受理。
- 公司正式宣布FDA受理daraxonrasib的NDA。市场反应:原文称RVMD盘后报186.45美元，较183.03美元前收上涨1.87%。
关键理由
- FDA受理daraxonrasib用于既往治疗转移性胰腺导管腺癌的NDA，属于监管路径推进而非最终获批。
- 该药此前已披露突破性疗法、孤儿药、扩展用药和优先审评相关进展，ASCO/NEJM数据也已传播，受理本身增量低于疗效读出或正式批准。
- 原文显示RVMD前收183.03美元、盘后186.45美元，上涨1.87%，市场已有温和正向反应但不是强重定价。
主要风险
- NDA受理到正式批准仍有审评和标签风险，当前交易更像追逐已预期的监管进度。
- 股价接近过去一年高位区间上沿，若无明确PDUFA日期或批准结果，短线赔率不足。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-07 · 影响 weakens
发现EMA分阶段审评和NDA接近完成的前序公告，说明本次受理不是完全突发。
检索:Revolution Medicines daraxonrasib NDA accepted FDA July 2026 prior EMA phased review expanded access 原文 ↗
原文全文
展开原文 · 2,344 字
Revolution Medicines, Inc. (RVMD) announced that the U.S. FDA has accepted for review its New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for patients with metastatic pancreatic ductal adenocarcinoma.
Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, often linked to mutations in the RAS gene family. Daraxonrasib is designed to inhibit RAS, the primary driver of pancreatic cancer, and the application is supported by results from the Phase 3 RASolute 302 trial.
This global, randomized study compared Daraxonrasib to standard chemotherapy in previously treated metastatic PDAC patients, with or without identified RAS mutations. The trial met all primary and key secondary endpoints, showing unprecedented improvements in overall survival and progression-free survival.
Patients treated with Daraxonrasib also reported delayed deterioration in cancer-related pain, overall health status and quality of life, compared to chemotherapy. The safety profile was considered manageable. Results were presented at the ASCO 2026 meeting and published in the New England Journal of Medicine.
The FDA has previously granted Daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation, and the NDA has been selected for the FDA Commissioner's National Priority Voucher pilot program, which accelerates review of medicines addressing critical health priorities.
CEO Mark A. Goldsmith stated that the acceptance marks an important step toward potentially offering patients a new targeted therapy and advancing a new class of RAS-focused medicines for pancreatic cancer.
RVMD has traded between $34.00 and $193.82 over the past year. The stock closed Wednesday's trading at $183.03, down 0.14%. During the after-hours trading session, the stock is at $186.45, up 1.87%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 17, 2026 16:34 ET A slew of U.S. data was released during the week that threw light on trends in prices and spending. Separately, survey data reflected the consumer mood amid easing inflationary pressures. In Europe, economic output figures from the U.K. were the main news. Meanwhile, China dominated the economics news scene in Asia as the country released the latest gross domestic product and external trade data.
Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, often linked to mutations in the RAS gene family. Daraxonrasib is designed to inhibit RAS, the primary driver of pancreatic cancer, and the application is supported by results from the Phase 3 RASolute 302 trial.
This global, randomized study compared Daraxonrasib to standard chemotherapy in previously treated metastatic PDAC patients, with or without identified RAS mutations. The trial met all primary and key secondary endpoints, showing unprecedented improvements in overall survival and progression-free survival.
Patients treated with Daraxonrasib also reported delayed deterioration in cancer-related pain, overall health status and quality of life, compared to chemotherapy. The safety profile was considered manageable. Results were presented at the ASCO 2026 meeting and published in the New England Journal of Medicine.
The FDA has previously granted Daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation, and the NDA has been selected for the FDA Commissioner's National Priority Voucher pilot program, which accelerates review of medicines addressing critical health priorities.
CEO Mark A. Goldsmith stated that the acceptance marks an important step toward potentially offering patients a new targeted therapy and advancing a new class of RAS-focused medicines for pancreatic cancer.
RVMD has traded between $34.00 and $193.82 over the past year. The stock closed Wednesday's trading at $183.03, down 0.14%. During the after-hours trading session, the stock is at $186.45, up 1.87%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 17, 2026 16:34 ET A slew of U.S. data was released during the week that threw light on trends in prices and spending. Separately, survey data reflected the consumer mood amid easing inflationary pressures. In Europe, economic output figures from the U.K. were the main news. Meanwhile, China dominated the economics news scene in Asia as the country released the latest gross domestic product and external trade data.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。